TriLink Biotechnologies

TriLink Biotechnologies is a long-standing, privately-held company based in San Diego that provides essential tools and services for the development of RNA-based therapeutics and diagnostics. Its core expertise lies in the synthesis of highly modified nucleic acids, with flagship technologies including its CleanCap® co-transcriptional capping reagent for mRNA and its novel ModTail™ technology for enhancing protein expression. Operating primarily as a platform and services business, TriLink supports a vast academic and biopharmaceutical clientele, from early research through commercial-scale GMP manufacturing, positioning it as a foundational player in the RNA ecosystem.

Proprietary nucleic acid modification and manufacturing platform, including CleanCap® co-transcriptional capping, ModTail™ for enhanced expression, and capabilities for synthesizing a wide array of modified oligos and mRNAs.

TriLink competes in several segments: as a reagent/kits supplier against giants like Thermo Fisher Scientific and New England Biolabs; as a custom oligo manufacturer against companies like Integrated DNA Technologies (IDT); and as an mRNA CDMO against firms like Aldevron, Lonza, and CureVac AG's CDMO business. Its differentiation lies in its deep expertise in modifications, the industry-standard CleanCap® technology, and its integrated service offering.